Sanford C. Bernstein started coverage on shares of ConvaTec Group (OTCMKTS:CNVVY – Get Rating) in a research report released on Tuesday morning, The Fly reports. The brokerage issued an outperform rating on the stock.
Several other equities analysts have also recently issued reports on CNVVY. JPMorgan Chase & Co. boosted their price target on shares of ConvaTec Group from GBX 275 ($3.31) to GBX 381 ($4.58) in a research report on Friday, November 18th. Jefferies Financial Group started coverage on shares of ConvaTec Group in a research report on Tuesday, November 22nd. They set a buy rating on the stock. Liberum Capital started coverage on shares of ConvaTec Group in a research report on Friday, November 18th. They set a buy rating on the stock. Morgan Stanley boosted their price target on shares of ConvaTec Group from GBX 227 ($2.73) to GBX 235 ($2.83) in a research report on Monday, November 14th. Finally, Barclays upped their price objective on shares of ConvaTec Group from GBX 290 ($3.49) to GBX 295 ($3.55) in a report on Tuesday, January 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, ConvaTec Group presently has a consensus rating of Moderate Buy and a consensus price target of $285.25.
ConvaTec Group Price Performance
Shares of OTCMKTS:CNVVY opened at $10.80 on Tuesday. The company has a 50-day moving average price of $11.56 and a 200-day moving average price of $10.71. ConvaTec Group has a 12 month low of $8.69 and a 12 month high of $12.23.
About ConvaTec Group
ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions.
- Get a free copy of the StockNews.com research report on ConvaTec Group (CNVVY)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.